Therefore, pharmacologic activation of Sirt1, Lxr and Fxr, which has been implicated in the pathogenesis of NAFLD, may be a potential therapeutic target for treating NAFLD. This evidence concerns the gene SIRT1 and metabolic dysfunction-associated steatotic liver disease.